“…The clinical significance of these results comes from their findings that when PMDD women are divided into lower versus higher symptom severity groups, the more severe PMDD symptom groups respond with less of a reduction in SEV (Sundstrom et al, 1997b(Sundstrom et al, , 1998 and with lower sedation ratings (Sundstrom et al, 1998) in response to benzodiazepines. Since there is no evidence that PMDD women differ in the density or affinity of peripheral benzodiazepine receptors, at least as measured on lymphocytes (Daly et al, 2001), the findings of Sundstrom and colleagues indicate diminished functional sensitivity of GABA A receptors in PMDD. This is consistent with studies finding modest or no clinical efficacy with benzodiazepine treatment for PMDD (Schmidt et al, 1993;Freeman et al, 1995;Evans et al, 1998), though exceptions exist (Harrison et al, 1987), and with lack of clinical benefit associated with a progesterone intervention or with progesterone induction of supraphysiologic levels of 5α-and 5β-progesterone metabolites Vanselow et al, 1996;see Wyatt et al, 2001 for review).…”